



**NORTHWEST  
BIOTHERAPEUTICS**

4800 Montgomery Lane  
Suite 800  
Bethesda, MD 20814

t (240) 497-9024 [www.nwbio.com](http://www.nwbio.com)  
f (240) 627-4121 OTCQB: NWBO

**For Immediate Release on Wednesday, December 11, 2019**

**Northwest Biotherapeutics (OTCQB: NWBO) Announces Presentation**

**At Inaugural Glioblastoma Drug Development Summit**

*NW Bio CTO To Highlight History Of DCVax®-L and Phase III Clinical Trial*

BETHESDA, Md., December 11, 2019 - Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, Chief Technical Officer of NW Bio, is presenting at 11:40 a.m. today at the inaugural Glioblastoma (GBM) Drug Development Summit being held at the Westin Boston Waterfront Hotel in Boston, Massachusetts.

The title of Dr. Bosch’s presentation is DCVax®-L Phase III Clinical Trial: Development of Dendritic Cell Based Immunotherapies for Cancer -- Where Are We, and How Did We Get Here.

The conference is not webcasting the presentations. However, Dr. Bosch’s presentation slides will be made available on NW Bio’s website after the conference session. ([www.nwbio.com](http://www.nwbio.com))

**About Northwest Biotherapeutics**

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company’s lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an “orphan disease.” The Company is also pursuing development of DCVax®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial, and is preparing for Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.

***Disclaimer***

*Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “believe,” “intend,” “design,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We cannot guarantee that we actually will achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company’s ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company’s products will demonstrate safety and efficacy, risks related to the Company’s ongoing ability to raise additional capital, and other risks included in the Company’s Securities and Exchange Commission (“SEC”) filings. Additional information on the foregoing risk factors and other factors, including Risk*

*Factors, which could affect the Company's results, is included in its SEC filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.*

## **CONTACTS**

Dave Innes  
804-513-4758 [dinnes@nwbio.com](mailto:dinnes@nwbio.com)

Les Goldman  
240-234-0059 [lgoldman@nwbio.com](mailto:lgoldman@nwbio.com)

Northwest Bio Therapeutics | 4800 Montgomery Lane, Suite 800, Bethesda, MD 20814

[Unsubscribe {recipient's email}](#).

[Update Profile](#) | [About Constant Contact](#)

Sent by [dinnes@nwbio.com](mailto:dinnes@nwbio.com)